Skip to main content
Year archive

Innovent Biologics, Inc. — 2019 filings

All 54 regulatory filings released by Innovent Biologics, Inc. (1801) in 2019, sourced directly from the official regulator.

54 Filings
2019 Period
2019 filings (54)
Filing Released Lang
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF ANTI-LAG-3 MONOCLONAL ANTIBODY IN CHINA
Regulatory Filings
2019-12-06 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2019
Major Shareholding Notification
2019-12-05 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2019-12-04 English
INSIDE INFORMATION ANNOUNCEMENT - TYVYT (SINTILIMAB INJECTION) IS INCLUDED IN THE NEW CATALOGUE OF NATIONAL REIMBURSEMENT DRUG LIST
Regulatory Filings
2019-11-28 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF ANTI-PD-1/HER2 BISPECIFIC ANTIBODY IN CHINA
Regulatory Filings
2019-11-26 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2019
Capital/Financing Update
2019-11-06 English
Next Day Disclosure Return
Transaction in Own Shares
2019-10-18 English
COMPLETION OF PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2019-10-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2019
Regulatory Filings
2019-10-08 English
PLACING OF EXISTING SHARES AND TOP-UP SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update
2019-10-04 English
2019 INTERIM REPORT
Interim / Quarterly Report H1 2019
2019-09-27 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2019
Share Issue/Capital Change
2019-09-05 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2019-08-29 English
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2019
Interim / Quarterly Report H1 2019
2019-08-28 English
INSIDE INFORMATION - AUTHORIZATION AND LICENSING AGREEMENT WITH LILLY
Regulatory Filings
2019-08-22 English
DATE OF BOARD MEETING
Report Publication Announcement
2019-08-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2019
Capital/Financing Update
2019-08-06 English
2018 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT
Environmental & Social Information
2019-07-28 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE III CLINICAL TRIAL OF TYVYT (SINTILIMAB INJECTION) AND IBI-305 COMBINED WITH CHEMOTHERAPY AS TREATMENT FOR PATIENTS WITH EGFRM NSQNSCLC AFTER E
Regulatory Filings
2019-07-25 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2019
Regulatory Filings
2019-07-07 English
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTS NEW DRUG APPLICATION FOR IBI-301, A BIOSIMILAR PRODUCT CANDIDATE TO RITUXIMAB (MABTHERA/RITUXAN)
Regulatory Filings
2019-06-27 English
GRANT OF SHARE OPTIONS AND RESTRICTED SHARES
Share Issue/Capital Change
2019-06-17 English
POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON JUNE 14,2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-14 English
POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 14, 2019
Declaration of Voting Results & Voting Rights Announcements
2019-06-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2019
Capital/Financing Update
2019-06-09 English
Form of Proxy for use at the Extraordinary General Meeting to be held on Friday, June 14, 2019
Proxy Solicitation & Information Statement
2019-05-23 English
GRANT OF OPTIONS TO A DIRECTOR UNDER THE POST-IPO ESOP, GRANT OF RESTRICTED SHARES TO A DIRECTOR UNDER THE RS PLAN AND NOTICE OF EXTRAORDINARY GENERAL MEETING
Proxy Solicitation & Information Statement
2019-05-23 English
NOTICE OF EXTRAORDINARY GENERAL MEETING
AGM Information
2019-05-23 English
VOLUNTARY ANNOUNCEMENT - TWO CLINICAL STUDIES WITH THE ANTI-CD20 MONOCLONAL ANTIBODY (IBI-301), A BIOSIMILAR PRODUCT CANDIDATE TO RITUXIMAB, MET PRIMARY ENDPOINTS
Regulatory Filings
2019-05-08 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2019
Share Issue/Capital Change
2019-05-07 English
NON-EXEMPT CONNECTED TRANSACTION - PROPOSED GRANT OF RESTRICTED SHARES TO A DIRECTOR AND GRANT OF RESTRICTED SHARES
Capital/Financing Update
2019-05-03 English
Form of Proxy for use at the Annual General Meeting to be held on Friday, June 14, 2019
AGM Information
2019-04-26 English
PROPOSED GRANTING OF GENERAL MANDATES TO BUY BACK SHARES AND TO ISSUE NEW SHARES, PROPOSED RE-ELECTION OF THE RETIRING DIRECTORS AND NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2019-04-26 English
NOTICE OF ANNUAL GENERAL MEETING
AGM Information
2019-04-26 English
2018 ANNUAL REPORT
Annual Report FY 2018
2019-04-26 English
CHANGE OF DATE OF ANNUAL GENERAL MEETING AND EXTRAORDINARY GENERAL MEETINIG&#x3b; AND CHANGE OF BOOK CLOSURE PERIOD
Regulatory Filings
2019-04-25 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF IBI-318, A RECOMBINANT FULLY HUMAN BI-SPECIFIC ANTIBODY
Regulatory Filings
2019-04-24 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL TRIAL OF IBI-302, A NOVEL RECOMBINANT FULLY HUMAN BI-SPECIFIC FUSION PROTEIN TARGETING VEGF AND COMPLEMENT PROTEINS, FOR THE TRE
Regulatory Filings
2019-04-18 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2019
Share Issue/Capital Change
2019-04-07 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE IIA CLINICAL STUDY OF IBI-306, AN ANTI-PCSK9 MONOCLONAL ANTIBODY
Regulatory Filings
2019-03-21 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED WITH ANTI-CD47 MONOCLONAL ANTIBODY IN A PHASE I CLINICAL TRIAL IN THE U.S.
Regulatory Filings
2019-03-19 English
GRANT OF SHARE OPTIONS
Capital/Financing Update
2019-03-18 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2018
Annual Report FY 2018
2019-03-14 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2018
Annual Report FY 2018
2019-03-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2019
Regulatory Filings
2019-03-06 English
VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN A CLINICAL TRIAL OF PD-1 MONOCLONAL ANTIBODY TYVYT(SINTILIMAB INJECTION) IN COMBINATION WITH ANTI-VEGF MONOCLONAL ANTIBODY IBI-305 AS FIRST LINE TREATMENT
Regulatory Filings
2019-02-28 English
DATE OF BOARD MEETING
Report Publication Announcement
2019-02-27 English
VOLUNTARY ANNOUNCEMENT - COLLABORATION WITH CHIPSCREENBIOSCIENCES TO EVALUATE COMBINATION THERAPY IN PATIENTS WITH ADVANCED COLORECTAL CANCER
Regulatory Filings
2019-02-17 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN A PHASE I CLINICAL STUDY OF IBI-101, AN ANTI-OX40 ANTIBODY
Regulatory Filings
2019-02-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2019
Major Shareholding Notification
2019-02-11 English
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION APPROVES INVESTIGATIONAL NEW DRUG APPLICATION FOR IBI-318, A BI-SPECIFIC ANTIBODY
Regulatory Filings
2019-02-07 English
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION ACCEPTS NEW DRUG APPLICATION FOR IBI-305, A BIOSIMILAR PRODUCT CANDIDATE TO BEVACIZUMAB (AVASTIN)
Regulatory Filings
2019-01-29 English
VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED WITH ANTI-CD47 MONOCLONAL ANTIBODY IN A PHASE I CLINICAL TRIAL
Regulatory Filings
2019-01-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2018
Share Issue/Capital Change
2019-01-07 English